APA (7th ed.) Citation

Garcia-Manero, G., Gaddh, M., Platzbecker, U., Lindsley, R. C., Larson, S. M., Chevassut, T., . . . Zeidan, A. M. (2025). A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Annals of Hematology, 104(3), 1577. https://doi.org/10.1007/s00277-024-06081-4

Chicago Style (17th ed.) Citation

Garcia-Manero, Guillermo, et al. "A Phase 1 Study of Durvalumab as Monotherapy or Combined with Tremelimumab with or Without Azacitidine in Patients with Myelodysplastic Syndrome." Annals of Hematology 104, no. 3 (2025): 1577. https://doi.org/10.1007/s00277-024-06081-4.

MLA (9th ed.) Citation

Garcia-Manero, Guillermo, et al. "A Phase 1 Study of Durvalumab as Monotherapy or Combined with Tremelimumab with or Without Azacitidine in Patients with Myelodysplastic Syndrome." Annals of Hematology, vol. 104, no. 3, 2025, p. 1577, https://doi.org/10.1007/s00277-024-06081-4.